Literature DB >> 21576653

Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database.

Maurizio Landolina1, Maurizio Gasparini, Maurizio Lunati, Saverio Iacopino, Giuseppe Boriani, Carlo Bonanno, Antonello Vado, Alessandro Proclemer, Alessandro Capucci, Chantal Zucchiatti, Sergio Valsecchi, Renato P Ricci, Massimo Santini.   

Abstract

BACKGROUND: Long-term data on device-related untoward events in patients receiving defibrillators for resynchronization therapy (CRT-D) are lacking. We quantified the frequency of repeat invasive procedures and the nature of long-term complications in current clinical practice and examined possible predictors of device-related events and their association with long-term patient outcome. METHODS AND
RESULTS: We analyzed data from 3253 patients who underwent de novo successful implantation of CRT-D and were followed up for a median of 18 months (25th to 75th percentiles: 9 to 30) in 117 Italian centers. Device-related events were reported in 416 patients, and, specifically, surgical interventions for system revision were described in 390 patients. Four years after the implantation procedure, 50% of patients underwent surgical revision for battery depletion and 14% for unanticipated events. For comparison, at 4 years battery depletion occurred in 10% and 13% of patients who received single- and dual-chamber defibrillators at the study centers, and unanticipated events were reported as 4% and 9%, respectively. In CRT-D, infections occurred at a rate of 1.0%/y, and the risk of infections increased after device replacement procedures (hazard ratio, 2.04; 95% confidence interval, 1.01 to 4.09; P=0.045). Left ventricular lead dislodgements were reported at a rate of 2.3%/y and were predicted by longer fluoroscopy time and higher pacing threshold on implantation. Device-related events were not associated with a worse clinical outcome; indeed, the risk of death was similar in patients with and without surgical revision (hazard ratio, 0.90; 95% confidence interval, 0.56 to 1.47; P=0.682).
CONCLUSIONS: In current clinical practice device-related events are more frequent in CRT-D than in single- or dual-chamber defibrillators, and are frequently managed by surgical intervention for system revision. However, a worse clinical outcome is not associated with these events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01007474.

Entities:  

Mesh:

Year:  2011        PMID: 21576653     DOI: 10.1161/CIRCULATIONAHA.110.015024

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Repeated procedures at the generator pocket are a determinant of implantable cardioverter-defibrillator infection.

Authors:  Eduardo Arana-Rueda; Alonso Pedrote; Manuel Frutos-López; Juan Acosta; Beatriz Jauregui; Lorena García-Riesco; Álvaro Arce-León; Federico Gómez-Pulido; Juan A Sánchez-Brotons; Encarnación Gutiérrez-Carretero; Arístides de Alarcón-González
Journal:  Clin Cardiol       Date:  2017-06-21       Impact factor: 2.882

Review 2.  Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?

Authors:  Khang-Li Looi; Nigel Lever; Anthony Tang; Sharad Agarwal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

3.  Management of Cardiac Electronic Device Infections: Challenges and Outcomes.

Authors:  Rikke Esberg Kirkfeldt; Jens Brock Johansen; Jens Cosedis Nielsen
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

4.  Reuse of pacemakers, defibrillators and cardiac resynchronisation devices.

Authors:  Raja J Selvaraj; R Sakthivel; Santhosh Satheesh; Ajith Ananthakrishna Pillai; Pascal Sagnol; Xavier Jouven; Bernard Dodinot; Jayaraman Balachander
Journal:  Heart Asia       Date:  2017-01-23

Review 5.  Adverse events following implantable cardioverter defibrillator implantation: a systematic review.

Authors:  Rebecca Persson; Amy Earley; Ann C Garlitski; Ethan M Balk; Katrin Uhlig
Journal:  J Interv Card Electrophysiol       Date:  2014-06-20       Impact factor: 1.900

6.  Epidemiology of cardiac implantable electronic device infections: incidence and risk factors.

Authors:  Hui-Chen Han; Nathaniel M Hawkins; Charles M Pearman; David H Birnie; Andrew D Krahn
Journal:  Europace       Date:  2021-06-23       Impact factor: 5.214

7.  Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Authors:  Maurizio Landolina; Antonio Curnis; Giovanni Morani; Antonello Vado; Ernesto Ammendola; Antonio D'onofrio; Giuseppe Stabile; Martino Crosato; Barbara Petracci; Carlo Ceriotti; Luca Bontempi; Martina Morosato; Gian Paolo Ballari; Maurizio Gasparini
Journal:  Europace       Date:  2015-05-14       Impact factor: 5.214

8.  Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings.

Authors:  Arn Migowski; Antonio Luiz Ribeiro; Marilia Sá Carvalho; Vitor Manuel Pereira Azevedo; Rogério Brant Martins Chaves; Lucas de Aquino Hashimoto; Carolina de Aquino Xavier; Regina Maria de Aquino Xavier
Journal:  BMC Cardiovasc Disord       Date:  2015-03-13       Impact factor: 2.298

9.  The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.

Authors:  Maurizio Landolina; Giovanni Morani; Antonio Curnis; Antonello Vado; Antonio D'Onofrio; Valter Bianchi; Giuseppe Stabile; Martino Crosato; Barbara Petracci; Carlo Ceriotti; Luca Bontempi; Martina Morosato; Gian Paolo Ballari; Maurizio Gasparini
Journal:  Europace       Date:  2017-08-01       Impact factor: 5.214

10.  Cardiac resynchronization therapy device implantation guided by electroanatomic mapping system when contrast medium infusion is contraindicated.

Authors:  Vittorio Calzolari; Martino Crosato; Luca De Mattia; Paolo M Squasi; Stefano Indiani; Domenico Pacetta
Journal:  HeartRhythm Case Rep       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.